替诺福韦联合司美格鲁肽治疗乙肝相关肝源性糖尿病的临床研究  

Clinical Study of Tenofovir Combined with Semaglutide in the Treatment of Hepatitis B-related Hepatogenic Diabetes Mellitus

作　　者：刘煜 田红丽 刘涛 LIU Yu;TIAN Hongli;LIU Tao(Department of Gastroenterology,Bayingolin Mongol Autonomous Prefecture People's Hospital,Korla,Xinjiang Uygur Autonomous Region,841000 China)

机构地区：[1]巴音郭楞蒙古自治州人民医院消化内科,新疆库尔勒841000

出　　处：《糖尿病新世界》2023年第11期69-72,共4页Diabetes New World Magazine

摘　　要：目的研究替诺福韦联合司美格鲁肽治疗乙肝相关肝源性糖尿病的临床效果。方法选取2022年1—12月巴音郭楞蒙古自治州人民医院收治的90例乙肝相关肝源性糖尿病患者,依据用药方案不同进行分组,对照组(n=45)以替诺福韦与阿卡波糖联合治疗,研究组(n=45)以替诺福韦与司美格鲁肽联合治疗。治疗24周后,对比两组肝功能指标、血糖指标以及疾病疗效。结果治疗后,两组白蛋白(ALB)、谷丙转氨酶(ALT)以及谷草转氨酶(AST)水平比较,差异无统计学意义(P>0.05);治疗后,研究组空腹血糖(FPG)、餐后2 h血糖(2 hPG)糖化血红蛋白(HbA1c)水平均显著低于对照组,差异有统计学意义(P<0.05);研究组疾病治疗总有效率低于对照组,差异有统计学意义(P<0.05)。结论对于乙肝相关肝源性糖尿病患者同时给予替诺福韦与司美格鲁肽联合治疗疗效更佳,可有效促进患者的肝功能、血糖水平改善,且安全性较高,值得推广。Objective To study the clinical effects of tenofovir combined with semaglutide in the treatment of hepatitis B-related hepatogenic diabetes mellitus.Methods 90 patients with hepatitis B related hepatogenic diabetes admitted to the People's Hospital of Bayingolin Mongol Autonomous Prefecture from January to December 2022 were selected and grouped according to different medication schemes,the control group(n=45)was treated with a combination of tenofovir and acarbose,while the study group(n=45)was treated with a combination of tenofovir and smeglutide.After 24 weeks of treatment,compared the liver function indicators,blood glucose indicators,and disease efficacy between the two groups.Results After treatment,the levels of albumin(ALB),Alanine transaminase(ALT)and aspartate Transaminase(AST)were compared between the two groups,the difference was not statistically significant(P>0.05).After treatment,the levels of fasting plasma glucose(FPG),2-hour postprandial blood glucose(2 hPG)and glycated hemoglobin(HbA1c)in the study group were significantly lower than those in the control group,the difference was statistically significant(P<0.05).Conclusion The combination therapy of tenofovir and semaglutide was more effective in patients with hepatitis B-related hepatogenic diabetes mellitus,which can effectively promote the improvement of liver function and blood glucose level and has higher safety,and is worth promoting.

关 键 词：替诺福韦 司美格鲁肽 乙肝 肝源性糖尿病 

分 类 号：R587.1[医药卫生—内分泌]